Pfizer (PFE) stock is in focus as the company exceeds Street forecasts with its Q3 2025 results thanks mainly to its COVID ...

Pfizer offers a 7% dividend yield, lower COVID sales, oncology and cardiometabolic focus, and growth from Metsera and ...

And despite the sales slump in the U.S. this past quarter, Pfizer’s Prevnar dynasty still leads in pediatric pneumococcal vaccination worldwide and among conjugated pneumococcal vaccines for adults in ...

Global biopharmaceutical sales were $16.3 billion, down 6%. Primary Care sales were down 16% to $7.6 billion. Eliquis sales were up 22% to $2.0 billion. Prevnar sales were down 3% to $1.7 billion.

The fall COVID-19 vaccine season is starting slowly for Pfizer, with U.S. sales of its Comirnaty shots sinking 25% after ...

Pfizer reported lower third-quarter profit as demand for its Covid-19 vaccine and antiviral drug continued to decline.

Pfizer and Novo Nordisk's fight for obesity drug developer Metsera ratcheted up on Tuesday, as both companies submitted ...

Pfizer on Tuesday raised its full-year profit forecast for the second quarter in a row as robust demand for its blockbuster ...

Pfizer beat Q3 estimates with 87 cents EPS, raised 2025 profit guidance, as Eliquis and Vyndaqel growth offset declining COVID product sales.

We also have a huge number of stocks that are sinking under their own weight, high-quality companies, real companies that are ...

Pfizer Inc. (NYSE: PFE) is one of the best undervalued stocks to buy under $50. Pfizer Inc. (NYSE:PFE) received a rating ...

Pfizer (NYSE: PFE) beat earnings expectations decisively this morning, posting adjusted EPS of $0.87 against a $0.64 ...